24/7 Wall Street
17 Jan 2026, 10:36 UTC · 34w ago
Verdict
Headline takes no side. We score ACCD +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
SYFOVRE sales remained flat at $151 million in Q3 2025, with new patient share declining to 52%.
So whatStagnation in the company's primary revenue driver suggests a failure to scale and threatens the valuation based on aggressive growth.
More negative than 91% of claims this week
A structural patient access crisis and the cessation of co-pay assistance from the Good Days Foundation are hindering new patient enrollment for geographic atrophy treatments.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 86% of claims this week
EMPAVELI is the first and only approved treatment for C3G and IC-MPGN in the U.S., with potential for European expansion in December 2025.
So whatExclusive approval in a rare disease market provides significant pricing power and a long-term growth runway despite current slow execution.
More positive than 77% of claims this week
Apellis has reached 152 of its 225 guided cumulative patient start forms for EMPAVELI by September 2025.
More negative than 66% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
Shares surged following the acquisition of expanded commercial rights for a groundbreaking drug.
More positive than 88% of ticker scores this week
Oppenheimer initiated coverage with an Outperform rating and a $10 price target.
More positive than 82% of ticker scores this week
Shares popped following the announcement of a key regulatory approval.
More negative than 81% of ticker scores this week
The company is facing commercial execution failures, stagnant sales for SYFOVRE, and a high valuation that the current launch trajectory doesn't support.
More negative than 75% of ticker scores this week
The company cut IZERVAY guidance by $200 million due to a patient access crisis in the geographic atrophy market.
More positive than 60% of ticker scores this week
Mentioned as a stock that remains afloat due to innovation and a favorable regulatory environment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
4h ago
—
No price for ACCD right now — the quote feed didn't answer.
ACCD chart →
